Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Petosemtamab plus chemotherapy versus cetuximab plus chemotherapy in first-line RAS/BRAF wild-type unresectable or metastatic left-sided colorectal cancer
NL-OMON61769Phase 3Not yet recruiting
- Sponsor
- Genmab
- Start
- Aug 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of petosemtamab, cetuximab, irinotecan, oxaliplatin, fluorouracil and 1 more in colorectal cancer (CRC) (2 arms), sponsored by Genmab. Primary endpoints: Progression-free survival and Objective response rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
petosemtamabcetuximabirinotecanoxaliplatinfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON61769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61769.